Pacific Defense Selected for U.S. Army CMFF Program
27.3.2025 16:47:00 EET | Business Wire | Press release
Pacific Defense, the leader in C5ISR Modular Open Suite of Standards (CMOSS) products and integrated mission systems, has been selected for the contract definition phase of the United States Army’s CMOSS Mounted Form Factor (CMFF) Mounted Common Infrastructure (MCI), an Other Transaction Authority (OTA) contract evaluation. This phase aligns contract work scope and deliverables, fostering innovation and successful program execution post contract award. Leading a team of select industry partners that includes Thales Defense & Security Inc., BAE Systems, Palantir, MAXISIQ, Regal Technology Partners, and STC, an Arcfield company, Pacific Defense is ready to deploy a comprehensive capability set to accelerate the U.S. Army's vision for CMFF.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250327094467/en/
Pacific Defense CMOSS Mounted Form Factor (CMFF) revolutionizes communications, command, and control across U.S. Army ground and aviation platforms, enabling maneuver commanders to maintain a decisive advantage over peer and near-peer adversaries.
"The future of innovation for the warfighter and the defense industry is here today," said Travis Slocumb, CEO of Pacific Defense. "This milestone represents the culmination of years of hard work and collaboration with our Army and industry partners to deliver transformative solutions that are ready to meet the evolving needs of the modern battlefield. The foundational CMFF MCI investments across ground and aviation platforms unlocks an operating model that allows for rapid, iterative, and cost-effective insertion of hardware and software, significantly reducing the time to deploy and enhance systems.”
The CMFF program, led by PM Mission Command within Program Executive Office Command, Control, Communications, and Network (PEO C3N) at Aberdeen Proving Ground, is set to revolutionize communications, command, and control across U.S. Army ground and aviation platforms, enabling maneuver commanders to maintain a decisive advantage over peer and near-peer adversaries. Selected under an OTA, Mid-Tier Acquisition (MTA), this program accelerates the delivery of cutting-edge technology to the warfighter.
About Pacific Defense
Pacific Defense is purpose-built to drive the open systems transformation necessary to unlock rapid innovation and the power of commercial technology. Specializing in C5ISR and Electronic Warfare (EW) solutions for mission-critical environments, Pacific Defense leverages Modular Open Systems Architecture (MOSA) standards to deliver innovative, adaptable technology that enables faster response to emerging threats and evolving mission requirements. Learn more at www.pacific-defense.com and on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250327094467/en/
Contacts
Pacific Defense Media Contact
Lea Ramthun - marketing@pacific-defense.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rapid Medical™’s TIGERTRIEVER™ 13 Demonstrates Promising 90-Day Outcomes in DISTALS Trial, Reinforcing Pivotal Safety and Efficacy Findings7.5.2026 15:03:00 EEST | Press release
Rapid Medical™, a leading developer of advanced stroke treatment devices, today announced full results from the DISTALS randomized clinical trial, presented at the 11th European Stroke Organisation Conference (ESOC) in Maastricht, Netherlands, showing that TIGERTRIEVER™ 13 can safely restore blood flow to the brain and may improve clinical outcomes in patients with distal and medium vessel occlusion (DMVO) stroke. These findings build on earlier results showing a threefold improvement in restoring blood flow compared with medical management alone (p<0.0001), with no cases of serious brain bleeding observed in the treatment group. “These results show we can now safely restore blood flow and suggest this will make a meaningful difference for the right patients,” said Jeffrey L. Saver, MD, UCLA, and Principal Investigator of DISTALS. “What’s important is that both the device and the trial were designed specifically for distal stroke. By using a device built for these small vessels and mea
2 Million Downloads in Six Months: Tabelog’s Multilingual App Solves Critical Dining Pain Points for Travelers to Japan7.5.2026 15:00:00 EEST | Press release
Tabelog (https://tabelog.com/en/), one of Japan’s largest (*1) restaurant search and reservation services operated by Kakaku.com, Inc., has announced that its multilingual smartphone app (iOS/Android) for travelers visiting Japan has reached 2 million downloads (*2). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507560248/en/ 2M+ Downloads in 6 Months. The app also ranked #1 in downloads among Restaurant Search Apps in Japan for International Travelers (*3) in Taiwan, Hong Kong, South Korea, and the U.S., reflecting its immense popularity among global visitors. Download URL: https://tabelog-tourists.onelink.me/3eEh/iqkkho9r The Trusted Choice for Global Travelers: Solving Two Major Dining Pain Points in Japan For years, international visitors to Japan have faced two critical dining pain points: [Pain Point 1] The Information Gap: Most available resources are tailored for tourists, making it difficult to find the true loc
Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development7.5.2026 15:00:00 EEST | Press release
Altasciences, a fully integrated drug development solution company, andCertara (Nasdaq: CERT), a global leader in model-informed drug development (MIDD), today announced a strategic partnership to accelerate early-phase development programs. Fewer than half of preclinical drug candidates successfully reach first-in-human trials. Failures are driven by toxicity, poor pharmacokinetics, lack of efficacy, and challenges translating results from animals to humans. Many of these risks can be mitigated through a fully integrated model-informed drug development approach. Building on Altasciences’ Acceleration Platform, the integration of Certara’s strategic drug development services and biosimulation technology enables sponsors to establish proof of mechanism earlier, design more efficient studies, and make informed go/no-go decisions with greater confidence. By embedding modeling insights and digital workflows directly into development execution, study designs are optimized, dosing strategies
FIFA and Fanatics Expand Wide-Ranging Relationship to Include Historic Exclusive Collectibles Agreement (Trading Cards, Stickers and Trading Card Games)7.5.2026 14:00:00 EEST | Press release
In a landmark agreement expanding their already successful wide-ranging commercial relationship, FIFA and Fanatics have signed a long-term, exclusive collectibles licensing deal that features trading cards, stickers, and trading card games. The agreement, which will begin in full in 2031, covers both physical and digital collectibles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507105628/en/ An example of the product innovations that will be brought to fans under this new partnership is the highly sought-after player jersey patch program, including debut patches, which will be inserted into football trading cards from 2031 onward. All products will be designed and developed through Fanatics Collectibles and produced under the Topps brand. As a part of the deal, Fanatics will bring the magic to young people in every region of the world and support youth football globally by distributing more than $150 million in collect
DEFINITIVE Trial Reaches Major Milestone: All Centres Approved and More Than 50% Recruitment Achieved7.5.2026 12:21:00 EEST | Press release
The DEFINITIVE project, a landmark European Union-funded international phase III clinical trial evaluating the use of the HER2DX diagnostic assay to guide personalised treatment in early-stage HER2-positive breast cancer (BC), announces two major operational milestones at the ESMO Breast Cancer 2026 congress. Approvals have been obtained in the 7 participating countries, 33 clinicals sites are now open for patient recruitment. The trial has reached over 50% of its recruitment target, marking a pivotal moment on the path toward to transforming HER2-positive BC treatment. About the DEFINITIVE Project The DEFINITIVE project is a 5-year, prospective, open-label, randomised, two-arm phase III international clinical trial conducted across 44 centres in 7 European member states and associated countries. The trial aims to demonstrate that personalising treatment decisions for patients with early-stage (stage II to IIIA) HER2-positive BC using the HER2DX genomic diagnostic assay can improve pat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom